| DIRECT COMPETITOR COMPARISON | |
| CELG | AMGN | BMY | Pvt1 | Industry | | Market Cap: | 25.51B | 58.20B | 50.06B | N/A | 97.43M | | Employees: | 2,441 | 16,700 | 35,000 | 11,1741 | 65 | | Qtrly Rev Growth (yoy): | 17.30% | -1.60% | 4.40% | N/A | 19.70% | | Revenue (ttm): | 2.56B | 14.58B | 21.14B | 13.42B1 | 14.05M | | Gross Margin (ttm): | 91.04% | 84.99% | 72.39% | N/A | 63.92% | | EBITDA (ttm): | 573.33M | 6.71B | 6.32B | N/A | -12.30M | | Oper Margins (ttm): | 16.83% | 38.71% | 26.65% | N/A | -124.89% | | Net Income (ttm): | 373.27M | 4.74B | 3.79B | N/A | N/A | | EPS (ttm): | 0.802 | 4.585 | 1.933 | N/A | -0.32 | | P/E (ttm): | 69.20 | 12.54 | 13.07 | N/A | 16.41 | | PEG (5 yr expected): | 1.13 | 1.31 | 2.48 | N/A | 1.31 | | P/S (ttm): | 9.95 | 3.94 | 2.36 | N/A | 9.54 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.50 | 1.23% | 58.20B | 12.54 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.4399 | 0.13% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 50.90 | 1.03% | 13.51B | 29.02 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 47.01 | 0.11% | 42.31B | 18.18 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.47 | 0.58% | 9.00B | 1030.00 | | Teva Pharmaceutical Industries Limited | TEVA | 53.40 | 0.24% | 47.05B | 48.86 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.37 | 0.86% | 3.97B | 19.26 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.20 | -0.55% | 5.56B | 111.66 | | Pfizer Inc. | PFE | 18.26 | -0.27% | 147.35B | 15.17 | | Johnson & Johnson | JNJ | 63.11 | -0.11% | 174.13B | 13.78 | | GlaxoSmithKline plc | GSK | 42.68 | 0.95% | 108.19B | 13.42 | | Sanofi-Aventis | SNY | 39.15 | 1.35% | 102.23B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.759998 | 0.83% | 126.64B | 16.69 | | RHHBY.PK | 42.00 | 1.33% | N/A | N/A | | AstraZeneca plc | AZN | 46.19 | 2.08% | 66.98B | 9.28 | | Abbott Laboratories | ABT | 54.43 | 0.35% | 84.19B | 14.75 | | Bristol-Myers Squibb Co. | BMY | 25.27 | 0.44% | 50.06B | 13.07 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|